Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

WAY 163909

Known as: WAY-163909, WAY163909 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Neurochemical impact of the 5-HT2C receptor agonist WAY-163909 on monoamine tissue content in the rat brain
ABSTRACT Serotonin2C receptor (5‐HT2C) agonists are promising drugs for the treatment of neuropsychiatric diseases. However… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system
Intensification of craving elicited by drug-associated cues during abstinence occurs over time in human cocaine users while… Expand
  • figure 1
  • figure 2
  • figure 3
2014
2014
Variation within the serotonin (5-HT) 5-HT2C receptor system aligns with vulnerability to cocaine cue reactivity
Cocaine dependence remains a challenging public health problem with relapse cited as a major determinant in its chronicity and… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2013
Highly Cited
2013
Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.
Relapse to cocaine dependence, even after extended abstinence, involves a number of liability factors including impulsivity… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Serotonergic involvement in methamphetamine-induced locomotor activity: A detailed pharmacological study
The mechanism by which the psychostimulant methamphetamine (METH) increases locomotor activity may be attributable to indirect… Expand
  • figure 1
  • table 1
  • figure 8
Highly Cited
2008
Highly Cited
2008
The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test
Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has… Expand
2008
2008
WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
Introduction5-HT2C agonists, by decreasing mesolimbic dopamine without affecting nigrostriatal dopamine, are predicted to have… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like…
Serotonin-2C (5-HT2C) receptor antagonists and agonists have been shown to affect dopamine (DA) neurotransmission, with agonists… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2007
Highly Cited
2007
Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
RationaleActivation of one or more of the serotonin (5-HT) receptors may play a role in mediating the antidepressant effects of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2005
Highly Cited
2005
WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity
The pharmacological profile of WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE